Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Decline in Short Interest

Akari Therapeutics, Plc (NASDAQ:AKTX) saw a significant decrease in short interest in February. As of February 15th, there was short interest totalling 77,700 shares, a decrease of 38.7% from the January 31st total of 126,800 shares. Based on an average trading volume of 55,600 shares, the short-interest ratio is presently 1.4 days. Approximately 0.6% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of Akari Therapeutics in a research report on Sunday. They set a “sell” rating for the company.

Akari Therapeutics Trading Up 7.7 %

AKTX stock opened at $0.94 on Tuesday. The stock has a 50-day simple moving average of $1.15 and a 200-day simple moving average of $2.00. Akari Therapeutics has a 1 year low of $0.85 and a 1 year high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.